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Abstract
Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains.
They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of
Alzheimer’s dementia. This review will examine the origins of complement in the brain and the role of L-amyloid peptide
(AL) in complement activation in Alzheimer’s disease, an event that might serve as a nidus of chronic inflammation.
Pharmacology therapies that may serve to inhibit AL-mediated complement activation will also be discussed. ß 2000
Elsevier Science B.V. All rights reserved.
Keywords: L-Amyloid peptide; In£ammation; Neurodegeneration; Microglia
1. The natural history of Alzheimer’s disease
A multitude of factors (Fig. 1) contribute to a
reproducible set of neurochemical (e.g. cholinergic
de¢cits) and neuropathological (e.g. neuro¢brillary
tangles and amyloid plaques) changes that collec-
tively lead to Alzheimer’s disease (AD) dementia
[1^10]. Neuro¢brillary tangles (NFTs) are ¢brillar
aggregates of the hyperphosphorylated cytoskeletal
protein tau, which is associated with microtubules.
NFTs may be found both intracellularly and extra-
cellularly. The amyloid plaques appear to result from
the overproduction and/or reduced clearance of the
L-amyloid peptide (AL). AL accumulates mainly as
¢brillar deposits in the brain parenchyma and in the
leptomeningeal blood vessels of the hippocampus
and cortex. AL is proteolytically derived from the
L-amyloid precursor protein (LAPP) by, as yet, un-
identi¢ed proteases, termed L-secretase(s) and Q-sec-
retase(s). These secretases respectively cleave at the
NH2-terminus of the AL region in LAPP followed by
cleavage at the COOH-terminus of the AL region to
release the amyloid peptide. These endoproteases
produce AL that is 40 or 42 amino acids in length.
The longer form of AL ending in 42 is the dominant
form found in the amyloid plaques of AD brains.
Evidence increasingly implicates age, genes (e.g.
apolipoprotein E O4 or K2-macroglobulin) and in-
£ammation as crucial to the pathological process.
In addition, co-morbidities such as cardiovascular
and cerebral vascular diseases, or their risk factors,
appear also to modulate the expression of the classi-
cal histopathological and neurochemical markers of
AD, as well as its clinical manifestations. It has been
argued for the past decade that the accumulation of
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AL in the form of ¢brillar deposits in the CNS is
seminal to the development of AD. Familial cases
of AD in which genetic mutations of the genes for
LAPP or the presenilin proteins (PS1 and PS2) pro-
vide the strongest evidence supporting this convic-
tion. Such mutations lead to increased AL produc-
tion and virtually guarantee the development of AD.
However, it remains unresolved how AL exerts its
toxic e¡ects. Increasing numbers of investigators
¢nd that massive accumulations of AL can occur in
the brains from aged individuals without clinical signs
of dementia. At face value, these ¢ndings suggest
that factors in addition to AL are needed for the
development of AD dementia. This assertion is sup-
ported by the failure of transgenic mice overexpress-
ing human LAPP in the CNS to show classical signs
of AD pathology (i.e. nerve cell and synaptic loss)
despite forming obscene numbers of ¢brillar amyloid
deposits. One of the distinctive di¡erences found be-
tween brains bearing AL amyloid from control sub-
jects and the amyloid found in AD brains is markers
for in£ammation. Thus, sustained brain in£amma-
tion might be an essential co-factor in AD patho-
genesis.
The evidence for the importance of neuroin£am-
mation in AD rests on several lines of evidence. Over
20 epidemiological studies ¢nd that anti-in£amma-
tory drugs like indomethacin and ibuprofen reduce
the risk of AD [11^13]. Invariably, the presence of
AD dementia coincides with the detection of in£am-
matory markers around amyloid plaques and dystro-
phic neurites. These include activated microglia, the
resident macrophage of the brain, and activated as-
trocytes, plus elevation of various cytokines and
complement activation products. This spatial interre-
lationship implies that AL may exact in£ammatory
sequelae. In vitro studies show that AL can activate
cultured astrocytes [14] and microglia cells [15,16],
presumably through AL interactions with cell-surface
receptors [17^20]. The in£ammatory events might
also result from AL-mediated activation of the com-
plement system in the CNS, an issue on which we
shall now focus.
2. The complement system
Complement is a branch of the humoral immune
system involved in host defense [21]. Antibody and
antibody-independent activation of complement can
lead to in£ammation, opsonization and cytolysis.
Over 20 di¡erent proteins make up the major com-
plement pathways, the classical (C1 to C9) and the
alternative (C3^C9, factor B, D, P, H) (Fig. 2). The
classical pathway typically becomes activated when
the ¢rst protein in the pathway, C1q of C1, is bound
by an antibody or other activator [22]. This initiates
a proteolytic cascade, started by the activation of the
zymogen serine proteases C1r and C1s, which are
bound to C1q. The activation of C1 leads to the
sequential activation of C4 and then C3. The alter-
native pathway di¡ers from the classical pathway in
that activation begins at the level of C3 and involves
factors B, D, H and P. Proteolytic modi¢cation of
C3 by either pathway generates the anaphylatoxin
C3a, and forms a C3 product that can opsonize.
The activation product C3b possesses a newly ex-
posed thioester group that covalently attaches to
amines or hydroxyl groups. Once bound, the C3b
can act as an opsonin or as a C5 convertase, cleaving
C5 to produce the anaphylatoxin C5a and the C5
activation product, C5b. The C5b binds to mem-
Fig. 1. A scheme of AD pathogenesis re£ecting the coalescence of environmental, age-related and genetic factors in the development
of AD dementia. A detailed discussion of the hypothesis can be found in [3].
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branes beginning the formation of the membrane
attack complex (MAC) (C5bC6C7C8C9). MACs
(C5b^9) damage cells by assembling a lytic pore,
composed mainly of multiple C9 proteins, on cell
surfaces. The production of the proin£ammatory
anaphylatoxins, opsonization and MAC-mediated
cellular injury all ultimately lead to cytokine-medi-
ated recruitment and activation of immune cells to
the site of complement activation.
In addition to the proteins that make up the com-
plement pathways, there are also complement regu-
latory proteins and complement receptors [23,24].
The regulatory proteins such as C1 inhibitor, cluster-
in (SP40,40) and CD59 (see discussion below) inhibit
complement activation at di¡erent stages of the cas-
cade to guard against unremitting complement-in-
duced in£ammation. Receptors for anaphylatoxins
and activation products of C4 and C3 provide the
transducing mechanism mediating immune-cell che-
motaxis or activation.
All the components of the classical and alternative
complement pathways are found in the central nerv-
ous system (CNS) [23,24]. Although the pathogenic
role of complement is well recognized in diseases of
the periphery [25], the contribution of complement
activation to neurodegenerative disorders and dis-
eases is just now being realized [22,24,26]. The acti-
vation of complement can be detected in a multitude
of human neurodegenerative diseases, e.g. multiple
sclerosis (MS), myasthenia gravis (MG), head trau-
ma and stroke, and in animal models of these dis-
eases and disorders (see [22] for review). Blocking
complement activation in animal models of MS [27]
and MG [28] reduces brain damage, further implicat-
ing complement in these degenerative diseases of the
nervous system. The expected consequences of pro-
longed complement activation in the CNS are sus-
tained in£ammation resulting in the chronic recruit-
ment and activation of peripheral (e.g. neutrophils)
and resident immune cells (e.g. microglia). The e¡ects
of such extended in£ammation in brains can be seen
in transgenic mice chronically expressing in£amma-
tory cytokines in their CNS [29] or rats continuously
infused intracerebrally with the in£ammatory stimu-
lus lipopolysaccharide [30]. Of particular relevance to
AD, both models lead to memory impairment and
loss of cholinergic nerve cells in the hippocampus
[30,31].
Fig. 2. Diagram of the classical and alternative pathways of complement activation. fB, factor B; and fD, factor D.
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3. Complement activation in AD brains and in the
brains of LAPP transgenic mice
Although viewed for years as an immune-privi-
leged organ, the central nervous system contains
many immune system components. While breach of
the bloodöbrain barrier may allow peripherally pro-
duced proteins access to the brain, the role of blood^
brain barrier dysfunction in AD remains controver-
sial [18,32^34]. Studies over the last several years,
however, have demonstrated that the brain may syn-
thesize immunoglobulins [35] and components of the
complement system by both glia and nerve cells
[23,24], indicating that leakage across the blood^
brain barrier is not necessary for molecular media-
tors of in£ammation to appear in the CNS. The ¢rst
suggestion that complement proteins may be endog-
enous to the CNS came with the demonstration that
astrocytes in vitro could produce C3 and factor B
[36]. Since then, primary astrocyte and astroglioma
cultures have been shown to produce all of the acti-
vation components of both the classical and alterna-
tive pathways [37^41], as well as the terminal com-
plement components [42]. Astrocytes also express
receptors for the complement fragments C5a and
C3a, also known as anaphylatoxins. The C5a recep-
tor (C5aR) is expressed by astrocytes in the normal
brain and is upregulated in in£ammatory lesions in
vivo and by in£ammatory cytokines in vitro [43^45].
In addition, nerve cells also express all of the comple-
ment proteins, which also makes them a important
source of complement in the CNS.
In addition to astrocytes, microglia, which com-
prise approximately 10^20% of the brain’s cells, pro-
duce at least some complement proteins. Because of
the di⁄culty of establishing primary microglial cul-
tures and the paucity of microglial cell lines, less
work has been done examining complement protein
production by microglia. Microglial cultures have
been shown to express the genes for C1q, C2, C3
and C4, [46^51] while human monocyte/macrophage
cell lines, used as substitutes for microglia, also ex-
press the terminal components [42]. Since microglia
are commonly viewed as the brain’s resident macro-
phages. Expression of some complement proteins
(e.g. C1q, C1r, C1s, C2, C3, C4, and C9) by micro-
glia has been observed [52^54], but many investiga-
tors predict that microglia produce all of the comple-
ment components, as do peripheral macrophages
[55]. In addition, microglia express complement re-
ceptors and regulatory molecules. In fact, identi¢ca-
tion of microglia often depends on recognition of the
complement receptor type 3 (CR3), also known by
its components CD11b/CD18 or by the term MAC-
1, not to be confused with the membrane attack
complex [56,57]. Microglia also express complement
receptors type 1 (CR1; CD35) and type 4 (CR4),
which, together with CR3, act as phagocytic recep-
tors for complement-fragment opsonized complexes
[55,58,59]. These phagocytic receptors are expressed
by both resting and activated microglia, although
levels may be increased upon activation [60^62]. In
contrast, the receptor for C1q, C1qR, is found pri-
marily on process-bearing microglia, indicating con-
stitutive expression [48]. Recently, following the clon-
ing of the C5a receptor, its expression by microglia
has been unequivocally demonstrated [44]. Earlier
studies showed that C5a produced a chemotactic re-
sponse from microglia, suggesting that the cells ex-
pressed functional anaphylatoxin receptors [63]. The
presence of the C3a receptor on microglia has also
been demonstrated [64].
Perhaps the most surprising ¢nding is that some
complement components are produced by neurons.
Both C4 and the B-chain of C1q are produced by
neurons in culture, and both C4 and C1qB mRNA
and immunoreactivity are detected in neurons in the
brain [47,65]. Recent studies have demonstrated that
neurons express mRNAs for all of the classical com-
plement proteins as well [66] and that neurons may
be the source of much of the complement produced
in the brain [67,68]. Neurons may produce CR1, but
do not appear to express CR2 or CR3 [69]. Some
neuroblastoma cell lines do express C5aR [70] and
one study has suggested that C5aR is expressed by
neurons in the brain [71]. Another study has shown
that neuronal C5aR expression is increased during
infection [72]. Neuronal expression of C3aR has
not been documented. Thus, neurons in addition to
immune cells in the CNS may play an important role
in the elaboration of brain complement proteins in
neurodegenerative diseases.
Complement regulatory proteins are expressed
within the CNS as well. Astrocytes and microglia
express the soluble proteins clusterin [42] and C1-in-
hibitor [73,74]. Neuronal cell lines produce CD59
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and membrane co-factor protein (MCP, CD46), but
not decay-accelerating factor (DAF, CD55) [75]. As-
trocytes or astroglioma cell lines also express the
soluble inhibitors factor H, factor I, C4b binding
protein, properdin, and S-protein [49,65,76] and the
membrane proteins DAF and MCP [76^78]. Consti-
tutive expression of all three membrane-bound com-
plement regulatory proteins, CD46, CD55 and
CD59, is very high relative to the expression of the
activation pathway components, suggesting that as-
trocytes are well protected from the adverse e¡ects of
complement activation. In contrast, neurons are rel-
atively unprotected from complement attack. Neu-
rons or neuroblastoma cells have been described to
express C1-inhibitor and clusterin [65,74,79] and neu-
rons do express the membrane regulator CD59, al-
beit at low levels relative to astrocytes [80]. Neurons
cultured in the absence of glial cells display greatly
increased levels of CD59, suggesting that some astro-
cytic factor causes a downregulation of neuronal
CD59 (unpublished observations). Neuronal cell
lines also express CD55 and CD46 [81], but only
the expression of CD55 by neurons has been docu-
mented [82].
4. Complement expression and activation in AD and
animal models of AD
Complement proteins were ¢rst detected in Alz-
heimer’s disease senile plaques in the early 1980s
[83]. Initial studies described the detection of the ac-
tivation components of the classical pathway, namely
C1, C3 and its fragments, and C4 [84^87]. The pres-
ence of C3 activation fragments and the lack of solu-
ble components of activation indicated that these
complement proteins were bound to the plaque by
the process of activation [84]. In contrast, factor B
and properdin have not been detected in senile pla-
ques [8], implying that complement activation occurs
primarily via the classical pathway. We also have
found only activation of the classical complement
pathway in the CNS of a rat model of glutamate
receptor-mediated neurotoxicity [88]. Moreover, de¢-
ciency in factor B, an essential component for the
activation of the alternative complement pathway,
provides little protection against experimental aller-
gic encephalitis, unlike a C3 de¢ciency (S.R. Bar-
num, personal communication). However, it should
be noted that activation of one pathway generally
leads to the activation of the other, so it is likely
that the alternative pathway is activated, but at a
very low level.
The presence in AD of the terminal complement
components C5b^9, comprising the membrane attack
complex, remains controversial. While some investi-
gators cannot detect any of the terminal components
in AD brain and detect only low levels of the
mRNAs for some of the proteins [2,86,87], numerous
other investigators have consistently demonstrated
the presence of a neoepitope of the MAC [8,89,90].
Typically, the MAC is not detected in senile plaques,
but rather on dystrophic neurites and neuro¢brillary
tangles adjacent to the plaques. These results suggest
that complement activation occurs at the site of the
senile plaque, but bystander attack produces MAC
formation and insertion in adjacent neurons. Ultra-
structural studies have shown the presence of MAC
immunoreactivity associated with neuronal lyso-
somes and cytoskeletal proteins, suggesting that neu-
rons attempt to defend themselves against comple-
ment attack by internalization of the MAC [89].
Interestingly, non-demented individuals occasionally
present at autopsy with dense-core AL plaques and
neuro¢brillary tangles in most regards indistinguish-
able from those of AD patients, and, in fact, such
neuropathological changes may not be as uncommon
as previously thought. However, as opposed to the
AD patients, these controls displayed no terminal
complement components around plaques or tangles
[91]. These studies imply that the chronic in£amma-
tion, of which complement activation is a part, may
be at least partially responsible for the progression of
a patient to a state of dementia.
Besides the dense senile plaque deposits of AL, the
AD brain often contains deposits of AL, referred to
as cerebrovascular AL, or congophilic angiopathy,
around blood vessels [92]. As with the plaques, com-
plement proteins were found associated with the cer-
ebrovascular AL [93,94]. Pericytes, phagocytic cells
that exist in very close relationship to endothelial
cells in the cerebral microvasculature, produce C1q
as well as AL in culture [95]. Pericytes, therefore,
may be one source of in£ammatory molecules asso-
ciated with cerebrovascular amyloid.
Recent studies have suggested that classical path-
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way components may be greatly upregulated in AD.
The levels of mRNAs for the classical pathway pro-
teins are increased in AD brain compared to control
[68], and in fact may be increased to levels higher
than that seen in peripheral organs. The largest in-
creases occur in those areas of the brain displaying
the greatest pathology, such as the cortex. Areas of
the brain displaying little pathology, such as the cer-
ebellum, display small or no increases in complement
mRNA levels. Levels of complement proteins were
also increased, in addition to the mRNAs. For ex-
ample, increased levels of C1q protein were found in
AD cortex, but not in AD cerebellum [96].
The Alzheimer brain also contains di¡use plaques,
containing non-¢lamentous AL, in many regions of
the brain, including those generally not a¡ected by
the disease, such as the cerebellum. Unlike the senile
plaque, only the very earliest steps of complement
activation appear to occur in di¡use or primitive
plaques. For example, the C4 activation fragment,
C4d, was detected in di¡use plaques, while C3d, a
fragment resulting from the next step in the activa-
tion pathway, was not [97]. The MAC was not de-
tected in di¡use plaques either. The lack of complete
complement activation by di¡use plaques may ac-
count, at least in part, for the relative sparing of
brain areas containing only the di¡use deposits.
Multiple complement proteins have been detected
in cerebrospinal £uid (CSF). Some, such as C1q, C3,
C4, C9, CD59, and clusterin are normally at detect-
able levels in CSF [98^100]. In AD CSF, the levels of
clusterin are either elevated [101] or unchanged [102]
from control levels. C1q levels, conversely, are dra-
matically decreased in AD CSF compared to control,
and the decline in C1q correlates to the severity of
the disease [103]. Levels of other complement pro-
teins have been found to change in CSF with age,
but there is apparently no di¡erence between aged
controls and aged AD patients [104].
The Alzheimer brain apparently mounts a defense
against chronic complement attack. Levels of com-
plement regulatory proteins, such as clusterin [105],
C1-inhibitor [74,84], lactoferrin [94] and C4 binding
protein [106] are all upregulated in AD. In addition
to higher levels being found in the AD brain, C1-
inhibitor is detected in its cleaved form in AD [74].
Presence of the cleaved form, therefore, indicates
that C1 has been activated and then inhibited by
the C1-inhibitor. Immunostaining for CD59, which
is detected most strongly in endothelial cells in the
normal brain, in the AD brain predominates in the
same areas that stain for the MAC: dystrophic neu-
rites and neuro¢brillary tangles [107]. Finally, neu-
rons apparently internalize the MAC in an attempt
to limit cell damage (see above).
The LAPP gene is contained on human chromo-
some 21, which is trisomic in Down’s syndrome.
Most people with Down’s syndrome who live the
past 40 years of age develop both the neuropatho-
logical changes and the cognitive de¢cits seen in Alz-
heimer’s disease [108,109], supporting the hypothesis
that the LAPP gene is important in the initiation or
progression of AD. Consistent with the ¢ndings in
AD brain, complement immunoreactivity was de-
tected in association with dense core plaques in the
brains of older Down’s patients, but not with the
amorphous, di¡use deposits of AL seen in younger
Down’s brains [110]. There is also a sequential order
to the appearance of complement proteins in relation
to amyloid plaques. C1q, C3 and C4 have been de-
tected in early plaques whereas MAC appears later
[110], possibly coinciding with the onset of dementia.
Within the past several years, research into the
causes and possible treatment for AD has been ad-
vanced by the development of several di¡erent trans-
genic mouse models. Mice have been developed and
bred that are transgenic for human LAPP, both in its
normal form [111,112] and containing familial AD
producing mutations [113,114]. In addition, trans-
genic lines have been developed that express the
familial AD producing forms of another protein, pre-
senilin 1 (PS) [115^117]. In general, mice overexpress-
ing the normal human form of LAPP display little
AD-like pathology, although some cognitive de¢cits
have been described [111,118,119]. In contrast, sev-
eral lines of mice overexpressing familial AD forms
of LAPP develop AL plaques [113,120] and display
age-related impairments in learning and memory
[120]. Very recent studies have described signs of in-
£ammation, including complement proteins, associ-
ated with the plaques in these animals [121,122].
These in£ammatory markers increased with age.
However, complement proteins were not found con-
tiguous with all or even most plaques in these mice.
When care was taken to cross PS-LAPP double
transgenic mice onto a complement su⁄cient mouse
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strain, reactive microglia were found to surround the
AL plaques, whereas few microglia were seen in the
mouse strains that express low levels of complement
[123]. Also, AL activates mouse complement less ef-
¢ciently than human complement [124], and comple-
ment becomes associated with the plaques via com-
plement activation (see above). Taken together, these
results suggest that complement activation occurs in
mice transgenic for human Alzheimer’s disease-re-
lated proteins as long as the background strain of
mouse used is complement su⁄cient. In addition, a
mouse strain that is doubly (or triply) transgenic for
the AD-related proteins and human C1q may pro-
vide a better in vivo model for AL-mediated comple-
ment activation.
5. L-Amyloid peptide interactions with complement
proteins
Rogers and colleagues reported the ¢rst direct evi-
dence that aggregated AL alone activates comple-
ment [125]. AL absorbed to the plastic of microtiter
plates supports the activation of complement as in-
dicated by the deposition of the activation product
C3d on the wells. Since then, numerous laboratories
have replicated this ¢nding and shown that AL acti-
vation of complement can also occur in the £uid
phase by the classical and alternative pathways
[126^129]. This activation results in the production
of anaphylatoxins C3a [126,130] and C5a [128], the
opsonization of AL by the covalent addition of C3
[126^128] and the formation of the cytolytic MAC
[90]. In our studies, the formation of C3 activation
products, C3a and C3b, is a direct consequence of
the assembly of the classical C3 convertase (C4bC2a)
on the aggregated amyloid [130].
Fibrillar AL activates complement readily, whereas
non-¢brillar peptide does not [126^132]. The aggre-
gation of peptide through natural aging [128,132] or
by forced ¢bril formation at pH 6.0 [126] both sup-
port complement activation. However, on a molar
basis, aggregated AL1^42 activates complement
more potently than aggregated AL1^40 [126,131].
This di¡erence may re£ect the ability of AL1^42 to
form ¢brils with L-sheet conformation more readily
and at lower concentrations than AL1^40 [133]. It
should also be noted that AL interactions with C1q
leads to increased amyloid aggregation [134^136].
This interaction may be signi¢cant since C1q is often
found associated with incipient amyloid deposits
[110].
AL-mediated activation of the classical pathway
results from interactions between residues 14^26 of
the A chain of the collagen-like tail of C1q [131] and
the ¢rst 11 residues of AL [125,126,137] (Fig. 3). The
binding interaction between C1q and AL may be
mainly ionic since the ¢rst 11 residues of AL are
predominantly anionic while those of the C1q A
chain residues 14^26 are cationic [137]. Consumption
of C4 in human serum requires the presence of the
¢rst 11 amino acids of AL, and modi¢cation of the
aspartic acid at residue 7 by isomerization or by
substitution with asparagine reduces C4 consumption
[138]. We ¢nd that the C1q binding to aggregated AL
is reduced if the NH2-terminus of AL is truncated by
two amino acids (AL3^42) and is virtually eliminated
when using aggregated AL12^42 (unpublished obser-
vation). The rat sequence of AL1^42 which di¡ers
from the human sequences at three residues within
the ¢rst 16 amino acids also fails to bind C1q (un-
published observation). Interestingly, all the AL frag-
ments that failed to bind C1q still activate C3 in
human serum (unpublished observation), presumably
through the alternative (C1q independent) comple-
ment pathway. This also implies that C3 can be ac-
tivated by and binds to residues in the AL12^42 se-
quence. We have observed that C3 can bind to
aggregated AL1^42 and covalently modify the pep-
tide even in the absence of complement activation
[126]. This latter binding interaction appears to be
Fig. 3. Proposed sites of interaction between complement pro-
teins C1q and C3 with the AL1^42. Amino acids in italics,
Asp7 and Ser26, are suspected of being important for the bind-
ing of C1q collagen tail and C3, respectively.
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reasonably high a⁄nity. Studies on the displacement
of 0.015 WM iodinated apolipoprotein E binding to
¢brillar AL1^40 reveal that C3 has a 50% inhibitory
(IC50) value of 0.085 WM compared to that of 0.18
WM for C4 and s 1 WM for C1q (H. LeVine, unpub-
lished observation). These binding results suggest
that C3 and C1q bind to di¡erent sites on AL. How-
ever, there may be some overlap between the binding
sites for C1q and C3 on amyloid ¢brils. The level of
C1q binding to aggregated AL1^42 increases several
fold upon depletion of C3 from human serum (un-
published observation). The increased binding of
C1q to AL can be reduced upon restoring C3 to
the depleted serum (unpublished observation). Re-
cently, Bradt and Cooper showed that the AL resi-
dues 12 through 28 provide an activation/binding site
for C3 [139]. The serine at position 27 of AL1^42
provides a likely point for covalent attachment for
C3b opsonization (Fig. 3). Thus, any competition
between the binding of C3 and C1q might be ex-
plained by the possible apposition of their two bind-
ing sites on AL (see Fig. 3).
Complement activation can lead to cell death in
nerve cell cultures. The addition of human serum
to mixed rat hippocampal cell cultures results in het-
erologous complement attack leading to nerve cell
death. The addition of as little as 0.8 WM AL1^40
to human serum exacerbates the cell loss more than
treatment with 50 WM AL alone [140]. Similar results
have been obtained with human nerve cell lines
[141,142]. Moreover, the treatment of the SH-SY5Y
human neuronal cell line with AL stimulates comple-
ment production by these cells, which then results in
MAC formation [143].
We have employed cultured dog leptomeningeal
smooth muscle cells to examine further the conse-
quences of AL-mediated complement activation on
cell viability [144]. This system is unique in that cul-
tured smooth muscle cells treated with 10 WM AL1^
42 form a calyx of amyloid ¢brils on their cell sur-
faces and within several days undergo programmed
cell death (apoptosis) [145^147]. Addition of human
serum to AL-embedded smooth muscle cells results
in complement activation involving the binding of
C1q to the AL, the activation of C3 and the forma-
tion of MACs. Activation products of C3 and the
MACs can be visualized immunocytochemically in
association with the amyloid laden cells. In this in-
stance, the combination of complement activation
and AL does not increase cell death. Contrary to
expectations, treating the cultures with serum reduces
the amount of amyloid-induced toxicity despite the
activation of complement (unpublished observation).
Although surviving the induced complement attack
may be of immediate bene¢t to the smooth muscle
cell, it should be borne in mind that the amyloid-
embedded smooth muscle cells now become a poten-
tial nidus of chronic in£ammation. It remains to be
determined if such a scenario is played out in vivo,
but it merits noting that complement activation oc-
curs in the cerebral vascular amyloid found in the
leptomeningies of AD brains [94]. It may be specu-
lated that the anaphylatoxins produced as the result
of complement activation increase blood^brain bar-
rier permeability [148^151] and vasomotor activity,
events that could also locally compromise cerebral
perfusion.
6. Preventing complement activation in Alzheimer’s
brains
Several animal models of chronic neurodegenera-
tion bene¢t from complement inhibition. Morgan
and colleagues [27,28,152] have shown in a rodent
model of experimental allergic encephalitis (EAE)
soluble CR1, a cell surface inhibitor of complement
activation that binds activated C4 and C3, protects
animals from the development of MS-like symptoms.
Recently, Barnum and co-workers also reported that
overexpressing crry, another protein that inhibits
complement by binding activated C4 and C3, in
mouse brain also protects against EAE [153]. These
results provide some of the ¢rst indications that in-
hibiting complement activation has application to the
treatment of neurodegenerative disease. Tests in ani-
mal models of AD or AD patients have yet to be
done to determine if inhibiting complement activa-
tion exclusively will be bene¢cial. However, several
studies now show that conventional and non-conven-
tional means might be employed to prevent AL acti-
vation of complement [22].
In vitro studies have already begun to address how
to prevent AL-mediated complement activation. Ac-
tivation resulting from aggregated AL1^42 can be
prevented by inhibitors of the serine proteases C1r
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and C1s [126,130]. FUT-175, a potent inhibitor of
C1r and C1s as well as a number of other serine
proteases [154], prevents AL activation of comple-
ment via the classical pathway. This inhibition does
not prevent C1q from binding to AL, but it does
drastically diminish the amount of C3 activation.
Similarly, C1 inhibitor, a natural protein inhibitor
of C1r and C1s found in serum and tissue, also in-
hibits AL activation of complement [126]. Both com-
pounds also block complement activation in the
AL1^42 treated smooth muscle cell cultures [144].
Recent attempts to improve the selectivity and po-
tency of inhibitors of C1r and C1s have focused on a
series of benzoxazinone compounds [155^157]. Cur-
rently, only a small number of benzoxazinones have
been tested, but they are e¡ective in blocking AL-
mediated complement activation in vitro [22] or in
smooth muscle cell cultures (unpublished observa-
tion). Vaccinia virus complement control protein,
which inhibits by binding activated C4 and C3, has
also been recently reported to prevent in vitro com-
plement activation by AL [129]. Thus, multiple op-
portunities exist along the complement pathways to
intervene in its activation by AL.
An alternate strategy is to target AL itself as a way
of preventing complement activation. This can be
accomplished by small molecules binding to the AL
region needed for the interaction with C1q (AL1^11)
or C3 (AL12^28), or blocking the interaction of AL
with its binding site on C1q [131,158]. Congo red, a
histochemical stain for amyloids, blocks the binding
of C3 to AL1^42 ¢brils in vitro [130] and amyloid
¢brillized on smooth muscle cells in culture [127]. No
e¡ect on C1q binding to AL was detected in the
presence of Congo red. Interestingly, another stain
for amyloids, thio£avine S, had no such e¡ect on
the binding of complement proteins to aggregated
AL1^42 (unpublished observation). E¡orts have
also focused on blocking AL interactions with C1q
by competition with peptides that bear the same se-
quence as that region of C1q to which AL binds
[158].
Although none of the aforementioned approaches
have reached clinical trials in AD patients, anti-in-
£ammatory drugs have. The steroid prednisone has a
number of anti-in£ammatory e¡ects [159]. Clinical
trials in AD patients have been initiated with this
steroid, using a prednisone dose (10 mg/day) re-
ported to decrease serum levels of C3. However, re-
sults from this study failed to show a bene¢t of pred-
nisone compared to the placebo group in a year-long
study [160].
Hoechst-Marion-Roussel has been developing pro-
pentofylline for the treatment of AD. Propentofylline
is a xanthine derivative that acts as a cAMP/cGMP
phosphodiesterase inhibitor as well as increases the
extracellular concentration of adenosine by blocking
its cellular reuptake [161]. In vivo treatment with
propentofylline abates microglia activation and asso-
ciated damage in animal models of neurodegenera-
tion [162] and in cell culture studies [163], suggesting
that propentofylline has anti-in£ammatory activities.
However, it remains to be determined what, if any,
e¡ect this compound has on complement expression,
although it reportedly reduces expression of tumor
necrosis factor K and other cytokines by cultured
cells [164]. Propentofylline has been shown to have
bene¢cial e¡ects in a 52-week clinical trial in AD
patients [165].
Recently, two new NSAIDs, celecoxib (Searle/
Monsanto) and rofecoxib (Merck), that speci¢cally
inhibit cyclooxygenase-2 (COX-2) are being devel-
oped for the treatment of arthritis. Both compounds
are also under investigation for the treatment or pre-
vention of AD [166,167]. Several laboratories report
that anti-in£ammatory drugs e¡ectively block neuro-
toxicity resulting from chronic, low-level brain in-
£ammation [168] or by AL in cell cultures
[169,170]. It remains to be determined how the new
COX-2 inhibitors or other anti-in£ammatory drugs
a¡ect complement-mediated in£ammation.
7. Conclusions and commentary
Numerous epidemiological studies support inter-
vening or preventing AD by blocking in£ammatory
reactions that develop in the course of the disease.
Histopathological studies of AD brains suggest that
reactive microglia in association with amyloid depos-
its are the possible source of this in£ammation. Re-
cent in vitro studies implicate complement activation
by aggregated AL as a potential initiator of chronic
in£ammation through sustained glial cell activation,
since both astrocytes and microglia bear receptors
for the anaphylatoxins C3a and C5a. The anaphyla-
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toxins might also a¡ect blood £ow to those brain
regions exhibiting AL-mediated complement activa-
tion because C3a and to a greater extent C5a are
vasoactive. Moreover, the opsonization of amyloid
plaques by activated C3 and anaphylatoxin produc-
tion would, through chemotaxis, target microglial
attacks on those regions of AD brains with the great-
est numbers of amyloid deposits. Finally, this local-
ized complement activation leads to the formation of
MACs, which compromise the physiological integrity
of nerve cells upon inserting into their cell mem-
branes.
Presently, evidence from ALPP transgenic mice
and from non-demented patients with amyloid pla-
ques suggest that ¢brillar AL alone may not be su⁄-
cient to initiate brain in£ammation. It may be that
other factors such as an age-related increase in
steady-state levels of brain in£ammation [171], or
severe or subtle traumatic brain injury, resulting
from blunt trauma or cardiovascular disease, might
initiate in£ammation that is exacerbated by the pres-
ence of amyloid plaques. This may explain why brain
injury is more extensive in LAPP transgenic mice
than their control counterparts [172^175]. In this
context, it may be more appropriate to think of amy-
loid deposits as performing the same role as ‘oily
rags’ in initiating a con£agration. However, in the
case of AD, the con£agration is replaced by an un-
remitting, localized low-level in£ammation.
NSAIDs provide a promising, but largely untested,
approach to blocking the consequences of AL-medi-
ated in£ammation. A small clinical trial indicates
that the COX inhibitor, indomethacin, might have
a bene¢cial clinical e¡ect in AD patients [176]. How-
ever, speci¢c COX-2 inhibitors may provide the long-
term safety that is expected for chronic treatment or
prevention of AD brain in£ammation. E¡orts are
also directed toward preventing complement activa-
tion by AL from occurring by blocking the interac-
tion between complement proteins and AL, or inhib-
iting the proteolytic cascade that leads to
complement activation. One can also envision that
the elimination of amyloid plaques through blocking
AL production or its deposition will also diminish
in£ammation in AD brains. However, which of these
complement-directed approaches will prove the most
successful in treating AD or preventing the dementia
remains to be determined.
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